For the year ending 2025-12-31, ZOMDF had $1,926K increase in cash & cash equivalents over the period. -$18,216K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -81,858 |
| Depreciation | 2,055 |
| Amortization - intangible assets | 5,896 |
| Impairment loss | 55,833 |
| Loss on disposal of property and equipment | -68 |
| Stock-based compensation | 2,472 |
| Noncash portion of rent benefit | -42 |
| Accretion/amortization of available-for-sale securities | 722 |
| Equity in loss of nonconsolidated entities | -141 |
| Deferred tax expense | -428 |
| Purchased inventory | 548 |
| Prepaid expenses and deposits | -540 |
| Trade receivables | 590 |
| Other receivables | -499 |
| Accounts payable | -90 |
| Accrued income tax | -3 |
| Accrued expenses and other current liabilities | -989 |
| Customer contract liabilities | 50 |
| Other liabilities | 67 |
| Net cash used in operating activities | -17,649 |
| Securities matured | -20,521 |
| Investment in property and equipment | 567 |
| Acquisition of intangibles | 379 |
| Net cash provided by investing activities | 19,575 |
| Increase (decrease) in cash and cash equivalents | 1,926 |
| Effect of exchange rate changes on cash | 70 |
| Cash and cash equivalents, beginning of year | 7,021 |
| Cash and cash equivalents, end of period | 9,017 |
Zomedica Corp. (ZOMDF)
Zomedica Corp. (ZOMDF)